Beginning on the afternoon of March 21 and ending on March 24, the Academy of Managed Care Pharmacy’s AMCP 2023 will be held in San Antonio, Texas.
There will be 6 educational tracks to choose from: Biosimilar; Medications, Diseases, and the Impact of Managed Care; Legislative and regulatory trends; Focus on Managed Care Pharmacy; A study of managed care in action; and Paving the way for innovation.
Pre-conference activities will see a 90-minute panel discussion exploring the incorporation of value-based frameworks into the managed care arena and how they can be used to facilitate coverage decisions for various pharmaceuticals and health technologies. It will be led by Kimberly Westrich, MA, director of value and access strategy at AmerisourceBergen. Additional topics to be covered include the importance of certain data points—chief among them, comparative clinical effectiveness and outcomes data—and the Inflation Reduction Act.
“There really is a wealth of information. We’re going to do a little research, a little real-world application and even some policy predictions,” Westrich said. “From a research perspective, we’ve partnered with the National Board of Pharmacy to study how payers use value assessment information in decision making, and then we’ll have some information about how payers use that in the real world.”
Day 1 is packed with sessions that cover how to navigate the regulatory landscape of biosimilar use and explore the impact of interchangeability status, both of which have the potential to impact patient care; how prior authorization relates to participation in clinical trials, and data on these decisions can inform approaches to patient-centered care; addressing health disparities; and improving patient outcomes in several disease states, including β-thalassemia, HIV and cancer. There will also be a welcome breakfast in the morning for first-time meeting attendees and new AMCP members.
On Day 2, the morning will include engaging discussions on pharmaceutical market trends, drug development, and legislative and regulatory updates, and the afternoon will include sessions on biosimilars, a focus on advances in hemophilia treatment, and aligning payers and manufacturers for success within of value-based contracts. Late afternoon sessions cover alternative payment models and racial health disparities in medication adherence.
The last day of AMCP 2023 will be short and will end around noon. But before that, the morning will include satellite symposia on patient outcomes in acute myeloid leukemia and opioid analgesic therapy for chronic pain, as well as an in-depth educational session on the Inflation Reduction Act.
In addition, the Science and Innovation Halls will feature presentations on Rett syndrome, a rare neurodevelopmental disorder; zuranolone, which is being studied for use in major depressive disorder and postpartum depression (and not yet approved by the FDA); and the use of molecular diagnostics in oncology.
In addition to a total of 34 educational sessions, 14 satellite symposia and an exhibition with over 75 exhibitors, there will be 3 notable keynotes:
- Robin Roberts, the host of “Good Morning America,” who survived both breast cancer and myelodysplastic syndrome, for which she underwent a bone marrow transplant when her sister was found to be perfect, spoke Wednesday, March 22.
- Douglas M. Long, MBA, vice president of industry relations at IQVIA, and Susan A. Cantrell, RPh, CAE, will moderate “Healthcare and Pharmaceutical Market Trends 2022-2023” on Thursday, March 23.
- Leslie Fish RPh, PharmD, VP of Pharmacy at IPD Analytics, and Jeffrey Casberg, MS, RPh, will speak during the “2023 Specialty Pharma Line” on Friday, March 24, which Christina Barrington, PharmD, will moderate.